This Baidu Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
Wall Street analysts change outlook on top stocks, including BIDU and BMO. See their ratings and price targets on Benzinga's analyst page.
Read original at benzingaStocks · News reference
BioMarin Pharmaceutical Enters Global Exclusive License Agreement And Collaboration With n-Lorem Foundation To Develop A First-In-Disease, Antisense Oligonucleotide Medicine For People Living With ReNU Syndrome
Under the agreement, BioMarin and n-Lorem will collaborate to advance an investigational ASO candidate targeting the RNU4-2 (n.64_65insT) variant, which is estimated to account for approximately 75% of ReNU syndrome
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 27, 2026, 1:10 PM
- Checked
- Jul 27, 2026, 1:10 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.
Read original at benzingaBMO Capital Initiates Coverage On BioMarin Pharmaceutical with Outperform Rating, Announces Price Target of $98
BMO Capital analyst David Lebowitz initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform rating and announces Price Target of $98.
Read original at benzingaBioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment
BioMarin Pharmaceutical agrees to acquire Alesta Therapeutics for $275 million upfront, securing ALE1 for rare bone disease treatment.
Read original at benzinga